Is NCT07100990 recruiting in Chicago, IL?

Yes, NCT07100990 is currently recruiting participants at its Chicago, IL location. This optic neuritis clinical trial is actively enrolling qualified participants.

How do I join the optic neuritis clinical trial in Chicago?

To join this clinical trial in Chicago, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Chicago clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Optic Neuritis Clinical Trial in Chicago, IL

Who Can Participate

Exclusion Criteria

for each sub-trial are listed below: Optic Neuritis Sub-Trial: Inclusion criteria:

≥18 years of age

MRI orbits demonstrating evidence of new T2 hyperintensity and/or post-gadolinium contrast enhancement of the optic nerve(s) and meeting the clinical criteria for Optic Neuritis

Visual acuity 20/200 or worse

Within 8 days of onset of visual symptoms

Able to initiate PLEX within 72h of the first dose of HDCS (if randomized to the "Early PLEX" treatment arm)

Able to sign and date informed consent form

Willingness to comply with all study procedures and availability for the duration of the study Exclusion criteria:

Evidence of prior episode of optic neuritis in the affected eye (by history or ophthalmological evaluation)

Ophthalmological comorbidity that would significantly affect best corrected visual acuity or visual fields

Presence of any contraindication to receiving HDCS or PLEX, including, but not limited to, hemodynamic instability, significant bleeding/coagulopathy, or sepsis.

Any medical condition that, in the opinion of the investigator, may interfere with the patient's participation in the trial, pose any added risk for the patient, or confound the assessment of the patient (including but not limited to concurrent neurological disease and/or medical comorbidity)

Treatment with any investigational agent within 6 months of baseline or five half-lives of the investigational agent (whichever is longer)

Ongoing/prior treatment with immune-modulating/immunosuppressive therapy including:

Mycophenolate mofetil, azathioprine, methotrexate, fingolimod, siponimod, ponesimod, ozanimod, tocilizumab, satralizumab, eculizumab or ravulizumab within 3 months of randomization

Anti-CD20 (rituximab, ocrelizumab, ofatumumab, ublituximab) or anti-CD19 (inebilizumab) therapy within 6 months of randomization

Intravenous or subcutaneous immune globulin within 3 months of randomization

Plasma exchange within 3 months of randomization

Interferon-beta, glatiramer acetate, fumarates (dimethyl fumarate, monomethyl fumarate, diroximel fumarate) within 1 month of randomization

Teriflunomide use within prior 24 months

Systemic corticosteroid therapy (intravenous or oral; excluding inhaled or topical corticosteroids) within 1 month of randomization

Any previous treatment with alemtuzumab, cladribine, mitoxantrone or cyclophosphamide

Previous treatment with any immune-modulating or immunosuppressive therapy not mentioned above within 6 months of randomization or five-half-lives (whichever is longer) Transverse Myelitis Sub-Trial: Inclusion criteria:

≥18 years of age

Diagnosis of Transverse Myelitis (defined based on modified criteria adapted from the 2002 Transverse Myelitis Consortium Working Group; ALL are required)

Development of sensory, motor and/or autonomic symptomatology attributable to spinal cord dysfunction

Onset of symptoms to nadir \>12 hours

Demonstration of inflammation within the spinal cord by presence of intramedullary T2 lesion (post-gadolinium enhancing OR non-enhancing) on MRI

Expanded Disability Status Scale \[EDSS\] ≥3.0 (excluding visual and cerebral functional systems)

EDSS Pyramidal Functional System Score ≥ 2

Within 8 days of onset of motor symptoms

Able to initiate PLEX within 48h of the first dose of HDCS (if randomized to the "Early PLEX" treatment arm)

Able to sign and date informed consent form

Willingness to comply with all study procedures and availability for the duration of the study Exclusion criteria:

Pre-existing ambulatory, motor, sensory, or bowel/bladder disability of any cause that could confound trial assessments

Fulfillment of possible, probable or definite spinal cord infarction diagnosis per proposed diagnostic criteria (Zalewski et al. JAMA Neurology 2018)

History of radiation to the spine

High clinical suspicion for infectious etiology of myelitis (e.g., fever, rash or other findings)

Presence of any contraindication to receiving HDCS or PLEX, including, but not limited to, hemodynamic instability, significant bleeding/coagulopathy, or sepsis.

Treatment with any investigational agent within 24 weeks of baseline or five half-lives of the investigational agent (whichever is longer)

Ongoing/prior treatment with immune-modulating/immunosuppressive therapy including: Mycophenolate mofetil, azathioprine, methotrexate, fingolimod, siponimod, ponesimod, ozanimod, tocilizumab, satralizumab, eculizumab or ravulizumab within 3 months of randomization

Anti-CD20 (rituximab, ocrelizumab, ofatumumab, ublituximab) or anti-CD19 (inebilizumab) therapy within 6 months of randomization

Intravenous or subcutaneous immune globulin within 3 months of randomization

Plasma exchange within 3 months of randomization

Interferon-beta, glatiramer acetate, fumarates (dimethyl fumarate, monomethyl fumarate, diroximel fumarate) within 1 month of randomization

Teriflunomide use within prior 24 months

Systemic corticosteroid therapy (intravenous or oral; excluding inhaled or topical corticosteroids) within 1 month of randomization

Any previous treatment with alemtuzumab, cladribine, mitoxantrone or cyclophosphamide

Previous treatment with any immune-modulating or immunosuppressive therapy not mentioned above within 6 months of randomization or five-half-lives (whichever is longer)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT07100990) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Optic Neuritis Treatment Options in Chicago, IL

If you're searching for optic neuritis treatment options in Chicago, IL, this clinical trial (NCT07100990) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced optic neuritis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all optic neuritis clinical trials near you to find additional studies recruiting in your area.

Optic Neuritis Clinical Trial in Chicago, IL

Expert Care in Chicago

IRB Approved

No-Cost Care

Apply for This Chicago Location

Why Participate?

Simple Process

About This Optic Neuritis Study in Chicago